SS-31 Study Explained: SS-31 improves post-cardiac arrest brain injury by inhibiting microglial

Quick answer

For “SS-31 improves post-cardiac arrest brain,” in a rat model of cardiac arrest and resuscitation, SS-31 treatment was linked to improved survival rates, reduced neurological deficits, and lower levels of brain injury markers in the blood.¹

This is an animal study modeling a severe, acute injury. The controlled laboratory setting differs significantly from the variability of human cardiac arrest cases.¹ Filipino readers should keep that finding tied to the cited study and verify any local product claim separately.

What is SS-31, in plain language?

The catalog question is separate from the SS-31 improves post-cardiac arrest brain research question. A live card helps with navigation, while the cited source supports the scientific statement.

For “SS-31 improves post-cardiac arrest brain,” the measured outcome was clear: in a rat model of cardiac arrest and resuscitation, SS-31 treatment was linked to improved survival rates, reduced neurological deficits, and lower levels of brain injury markers in the blood.¹

Within “SS-31 improves post-cardiac arrest brain,” the source places the result in this setting: this study used a rat model of cardiac arrest followed by cardiopulmonary resuscitation. Researchers examined brain tissue for signs of ferroptosis (an iron-dependent form of cell death) and microglial polarization (a change in immune cell state) to understand the potential protective mechanisms.¹

For “SS-31 improves post-cardiac arrest brain,” the practical limitation is this: this is an animal study modeling a severe, acute injury. The controlled laboratory setting differs significantly from the variability of human cardiac arrest cases.¹

For “SS-31 improves post-cardiac arrest brain,” the paper’s main result was that in laboratory experiments, SS-31 was shown to interact with lipid membranes and reduce the aggregation of α-synuclein, a protein whose clumping is a hallmark of Parkinson's disease and related conditions.²

For “SS-31 improves post-cardiac arrest brain,” that result does not erase its main limit: these are fundamental lab studies using isolated proteins, artificial membranes, and cell lines. They do not show an effect on Parkinson's disease in a living organism.²

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the central study report?

The point is not to make SS-31 improves post-cardiac arrest brain sound weaker or stronger. It is to describe the finding at the same size as the source.

For “SS-31 improves post-cardiac arrest brain,” the study reported that in a mouse model of spinal cord injury, treatment with SS-31 was associated with improved locomotor recovery, reduced tissue damage, and increased preservation of nerve cells.³

Within “SS-31 improves post-cardiac arrest brain,” the setting matters: this study used a mouse thoracic contusion model, a common method for studying spinal cord injury. Researchers observed effects on both early injury markers (like apoptosis signaling) and longer-term indicators of neural remodeling.³

For “SS-31 improves post-cardiac arrest brain,” the main limit is equally important: this is an animal study. The complexity of human spinal cord injury and recovery is far greater, and these findings are an early step in understanding a potential mechanism, not a demonstration of a human treatment.³

What does the wider evidence add?

This SS-31 improves post-cardiac arrest brain question becomes simpler once research and product identity are given different jobs. One explains a finding; the other identifies a catalog entry.

For “SS-31 improves post-cardiac arrest brain,” researchers found that in a mouse model of ischemic stroke, a combination of SS-31 and nicotinamide mononucleotide (NMN) reduced brain damage and neurological deficits more effectively than either compound alone.⁴

Within “SS-31 improves post-cardiac arrest brain,” the study design provides the frame: this study used a middle cerebral artery occlusion/reperfusion (MCAO/R) model in mice, a standard model for ischemic stroke. The research focused on the combined therapy's modulation of the TREM2 receptor, which is involved in neuroinflammation.⁴

For “SS-31 improves post-cardiac arrest brain,” one caution belongs beside that result: this is an animal study testing a combination therapy. The results are specific to this combination in a mouse model and do not provide information on SS-31 alone in the context of human stroke.⁴

Which limits matter most?

That distinction keeps this SS-31 improves post-cardiac arrest brain finding useful. A narrow result can answer a real question without becoming a promise about every person or product.

For “SS-31 improves post-cardiac arrest brain,” the measured outcome was clear: in cell studies, SS-31 reduced markers of cellular senescence, such as senescence-associated beta-galactosidase (SA-β-gal) staining and the expression of proteins p16 and p21, in heart muscle cells exposed to radiation or the chemotherapy drug doxorubicin.⁵

Within “SS-31 improves post-cardiac arrest brain,” the source places the result in this setting: these findings come from experiments on rat cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in a laboratory setting. The cells were exposed to stressors (γ-radiation or doxorubicin) to induce a state of cellular senescence, a model for studying certain aspects of tissue damage.⁵

For “SS-31 improves post-cardiac arrest brain,” the practical limitation is this: these are cell-based studies. The results may not directly translate to effects in a living animal or human, and the models represent a specific type of cellular stress.⁵

How does the catalog identity fit?

The catalog question is separate from the SS-31 improves post-cardiac arrest brain research question. A live card helps with navigation, while the cited source supports the scientific statement.

For “SS-31 improves post-cardiac arrest brain,” the study reported that the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁶

Within “SS-31 improves post-cardiac arrest brain,” the setting matters: official Philippine regulatory verification service.⁶

For “SS-31 improves post-cardiac arrest brain,” the main limit is equally important: a portal record applies to the exact product or establishment named in that record.⁶

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers take away?

The point is not to make SS-31 improves post-cardiac arrest brain sound weaker or stronger. It is to describe the finding at the same size as the source.

For “SS-31 improves post-cardiac arrest brain,” researchers found that WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.⁷

Within “SS-31 improves post-cardiac arrest brain,” the study design provides the frame: WHO guidance on suspected falsified medical products and regulatory laboratory testing.⁷

For “SS-31 improves post-cardiac arrest brain,” one caution belongs beside that result: appearance alone cannot authenticate a product or establish a research outcome.⁷

Bottom line

For “SS-31 improves post-cardiac arrest brain,” the clearest reading is that in a rat model of cardiac arrest and resuscitation, SS-31 treatment was linked to improved survival rates, reduced neurological deficits, and lower levels of brain injury markers in the blood.¹

In the “SS-31 improves post-cardiac arrest brain” discussion, a portal record applies to the exact product or establishment named in that record.⁶ For Filipino readers, the research result and the exact local product record remain separate checks.

That approach keeps SS-31 informative without turning one study into personal advice, a universal promise, or proof about a catalog product.

Frequently asked questions

What is the short answer about SS-31?

For “SS-31 improves post-cardiac arrest brain,” the cited source gives a focused answer: in a rat model of cardiac arrest and resuscitation, SS-31 treatment was linked to improved survival rates, reduced neurological deficits, and lower levels of brain injury markers in the blood.¹ The conclusion stays tied to that study’s population, method, and measured outcome.

Does one positive result settle the whole topic?

For “SS-31 improves post-cardiac arrest brain,” no single result settles the whole topic. This is an animal study. The complexity of human spinal cord injury and recovery is far greater, and these findings are an early step in understanding a potential mechanism, not a demonstration of a human treatment.³ A useful result can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study context matter?

Within “SS-31 improves post-cardiac arrest brain,” this study used a middle cerebral artery occlusion/reperfusion (MCAO/R) model in mice, a standard model for ischemic stroke. The research focused on the combined therapy's modulation of the TREM2 receptor, which is involved in neuroinflammation.⁴ Changing the population, comparison, formulation, or endpoint would change the question, so those details belong beside the finding.

What should Filipino readers verify?

For “SS-31 improves post-cardiac arrest brain,” the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁶ Check the exact name and record shown by the official source instead of assuming that a familiar molecule name covers every listing.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In this SS-31 improves post-cardiac arrest brain guide, the cards are live catalog references for navigation. They do not prove study equivalence, turn research into a product claim, or suggest that the two items should be used together.⁸

Sources

Footnotes

1. SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization.. This study used a rat model of cardiac arrest followed by cardiopulmonary resuscitation. Researchers examined brain tissue for signs of ferroptosis (an iron-dependent form of cell death) and microglial polarization (a change in immune cell state) to understand the potential protective mechanisms. This is an animal study modeling a severe, acute injury. The controlled laboratory setting differs significantly from the variability of human cardiac arrest cases. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

2. Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. This research used biophysical techniques like fluorescence correlation spectroscopy and transmission electron microscopy to observe SS-31's interaction with α-synuclein and synthetic lipid vesicles. It also used neuroblastoma cells treated with α-synuclein oligomers to assess effects on cell health and mitochondrial function. These are fundamental lab studies using isolated proteins, artificial membranes, and cell lines. They do not show an effect on Parkinson's disease in a living organism. ↩ ↩²

3. Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.. This study used a mouse thoracic contusion model, a common method for studying spinal cord injury. Researchers observed effects on both early injury markers (like apoptosis signaling) and longer-term indicators of neural remodeling. This is an animal study. The complexity of human spinal cord injury and recovery is far greater, and these findings are an early step in understanding a potential mechanism, not a demonstration of a human treatment. ↩ ↩² ↩³ ↩⁴

4. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. This study used a middle cerebral artery occlusion/reperfusion (MCAO/R) model in mice, a standard model for ischemic stroke. The research focused on the combined therapy's modulation of the TREM2 receptor, which is involved in neuroinflammation. This is an animal study testing a combination therapy. The results are specific to this combination in a mouse model and do not provide information on SS-31 alone in the context of human stroke. ↩ ↩² ↩³ ↩⁴

5. Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.; Mitochondrial-Targeted SS-31 Attenuates the Doxorubicin-Induced Cardiomyoblast H9C2 Cell Senescence.. These findings come from experiments on rat cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in a laboratory setting. The cells were exposed to stressors (γ-radiation or doxorubicin) to induce a state of cellular senescence, a model for studying certain aspects of tissue damage. These are cell-based studies. The results may not directly translate to effects in a living animal or human, and the models represent a specific type of cellular stress. ↩ ↩² ↩³

6. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵

7. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩² ↩³

8. SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization.; Elamipretide (SS-31) promotes recovery by preserving mitochondrial bioenergetics and neural remodeling after spinal cord injury.; Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩